ABSTRACT
INTRODUCTION
Familial adenomatous polyposis is a rare, autosomal dominant disease characterized by hundreds or thousands of colorectal adenomas, resulting in a near 100% lifetime risk of colorectal cancer. In addition, familial adenomatous polyposis patients often develop extracolonic features, including upper gastrointestinal tumors, congenital hypertrophy of the retinal pigment epithelium (CHRPE), desmoid tumors and dental abnormalities. Familial adenomatous polyposis is caused by germ-line mutations in the adenomatous polyposis coli (APC) gene, and somatic APC mutations are found in up to 80% of sporadic colorectal cancers. Both familial adenomatous polyposis and sporadic tumors usually harbor biallelic APC mutations, resulting in constitutive activation of the Wnt signaling pathway by up-regulating the level of ␤-catenin (1, 2) .
Patients with MYH (homolog of Escherichia coli mutY)-associated polyposis have a phenotype similar to patients with mild familial adenomatous polyposis (3, 4) . However, the disease shows autosomal recessive inheritance. MYH-associated polyposis accounts for ϳ30% of patients with 15 to 100 adenomas, and ϳ10% of APC mutationnegative patients with classical polyposis (Ͼ100 adenomas; ref. 4) . Colorectal cancer associated with MYH-associated polyposis appears to have a prevalence similar to that associated with familial adenomatous polyposis (5) .
MYH-associated polyposis is caused by biallelic germ-line mutations in the base excision repair gene MYH (6) . Base excision repair is important in repairing oxidative DNA damage originating as a byproduct of normal cellular metabolism or from extrinsic sources. The most frequent mutagenic lesion is 7,8-dihydro-8-oxoguanine (8-oxo-G). 8-oxo-G can mispair with adenine during DNA replication and cause G:C to T:A transversions. The products of three human base excision repair genes, MTH1, OGG1, and MYH, act together to prevent 8-oxo-G-induced mutagenesis. In the nucleotide pool, MTH1 hydrolyzes 8-oxo-dGTP to 8-oxo-dGMP (7-9); OGG1 detects and removes 8-oxo-G generated in situ or incorporated into DNA during replication (10 -13); and MYH, an adenine-specific DNA glycosylase, scans the daughter strand after DNA replication and removes adenines mispaired with 8-oxo-G (14 -16) . MYH deficiency leads to an increased frequency of G:C to T:A mutations in genes such as APC and K-ras in MYHassociated polyposis tumors (17, 18) .
In contrast to MYH-associated polyposis patients, Myh-deficient mice do not seem to show increased tumor susceptibility. Mice homozygous for a loss-of-function Myh allele (Myh Ϫ/Ϫ ) showed no difference from wild-type littermates in terms of survival after 14 months or of tumor incidence after 15 to 17 months (19) . However, Myh and Ogg1"double knockout" mice displayed a marked increase of lymphomas and lung and ovarian tumors. Myh Ϫ/Ϫ mice have been shown to accumulate 8-oxo-G at an increased rate in the liver when compared with wild-type mice, although no age-dependent accumulation was detected in brain, small intestine, spleen, or kidney (20) .
We aimed at developing a mouse model for MYH-associated polyposis. We reasoned that, despite the data above, Myh deficiency might have some subtle effect on the intrinsic mutation rate that was insufficient to cause macroscopic tumor development on an otherwise wild-type genetic background. Because most colorectal tumors from MYH-associated polyposis patients seem to harbor biallelic APC mutations (17, 18), we crossed Myh-deficient mice with multipleintestinal-neoplasia (Apc Min/ϩ ) mice, which carry a nonsense mutation at codon 850 of the Apc gene. Apc Min/ϩ mice are predisposed to multiple adenomas, primarily in the small intestine. In addition, these mice have an increased risk of developing mammary tumors, desmoids, and epidermoid cysts (21 mice. Animals of the six groups arose at the expected Mendelian frequencies (P ϭ 1, 2 test). Genotyping. DNA was extracted from tail snips by using standard methods. All of the animals were genotyped for Apc and Myh with three-primer, allele-specific PCR assays (19, 22) ; all founder mice were homozygous for the sensitive allele of Mom1 (22) .
Counts of Tumors, Cystic Crypts, and Aberrant Crypt Foci. Mice were sacrificed at 110 to 130 days by CO 2 asphyxiation. The intestinal tract was removed and divided into four segments consisting of three equal lengths of small intestine (proximal, middle, and distal) and the whole of the large intestine. Each segment was flushed with PBS, opened longitudinally, and laid out on filter paper. The samples were fixed in Carnoy's medium for 3 hours and stored in 70% EtOH. Before analysis, preparations were stained with 0.2% methylene blue for 3 minutes and were washed in PBS for 20 minutes. Tumors were counted with a dissecting microscope at ϫ3 magnification, and categorized according to size with an inoculating loop with an inner diameter of 1 mm and an outer diameter of 2 mm. Cystic crypts in the small intestine and ACFs in the large intestine were counted at ϫ3 and ϫ5 magnification, respectively. Criteria used to identify ACFs were dark-blue staining, increased crypt size, and flat appearance hidden in the surrounding mucosa. All of the counts were done in duplicate by an observer (O. M. S.) blinded to the genotype of the mice. A subset of cases was counted by a second observer (C. T.) to confirm the first observer's results.
Histology. After tumor counting, the proximal small-bowel segment from five animals per study group (Apc
Ϫ/Ϫ ) was rolled up, embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E). In addition, selected large tumors of the small and large intestine were processed, as well as all detected mammary tumors. To examine the histology of colonic ACFs, serial transverse sections were prepared at 4 m. All samples were analyzed by a histopathologist (G. S.) blinded to the genotype of the mice.
DNA Extraction from Tumor and Normal Tissue. Tumors were dissected from the methylene blue-stained, whole-mount preparations with a dissecting microscope at ϫ3 magnification. A fresh scalpel was used for each sample, and care was taken to avoid the surrounding normal epithelium. In total, 134 small-bowel and 6 colonic tumors from 12 Apc Min/ϩ /Myh ϩ/ϩ mice, 147 small-bowel and 21 colonic tumors from 16 Apc Min/ϩ /Myh ϩ/Ϫ mice, and 167 small-bowel and 16 colonic tumors from 13 Apc Min/ϩ /Myh Ϫ/Ϫ mice were collected. Tail tissue and normal bowel epithelium were also sampled. DNA was extracted from these samples with standard methods.
Loss of Heterozygosity (Allelic Loss) Analysis at Apc and Myh. Loss of heterozygosity (LOH) at Apc was analyzed with a fluorescence-single-strand conformational polymorphism (F-SSCP) assay that distinguished the wild-type and Min alleles ( . PCR conditions consisted of 95°C for 5 minutes, 35 cycles of 95°C/55°C/72°C for 1 minute each, and a final step at 72°C for 10 minutes. The resulting PCR products were run at 18°C through a 50-cm capillary on the ABI 3100 and analyzed with Genotyper 2.5 software (Perkin-Elmer Applied Biosystems). Allelic loss was considered present if the relative ratio of normal-to-tumor peak area was Ͻ0.5 or Ͼ2, thereby allowing for contaminating normal tissue. The validity of the F-SSCP-LOH assay had been established with serial dilutions of Apc wild-type and Min alleles, and results were confirmed for selected samples by sequencing tumor DNA alongside normal DNA (details not shown). Loss of the wild-type Myh allele was analyzed with the same allele-specific PCR assay as for the genotyping, in which a 262-bp product is diagnostic of the wild-type allele and a 376-bp product is diagnostic of the targeted allele. The common forward primer was fluorescently labeled. PCR products were run on the ABI 3100 and allelic loss scored as above.
Mutation Analysis. Primer pairs amplifying coding regions and exonintron boundaries were designed for Apc exons 5 to 14, Myh exons 2 to 15, and K-ras exon 1. Apc codons 652 to 1648 (exon 15) were covered by 10 overlapping primer pairs. Details and PCR conditions are available from the authors. Apc and Myh were screened by F-SSCP analysis. In addition, areas of Apc rich in T/AGAA sequences that are particularly susceptible to G:C3 T:A mutation to chain termination codons in humans (codons 894-1357 and 1545-1648 encompassing 44 such sites) were analyzed by direct DNA sequencing (17, 18) . K-ras exon 1 was analyzed by direct DNA sequencing. For F-SSCP analysis, PCR products were run at 18°C and 24°C on the ABI 3100 and were analyzed with Genotyper 2.5 software. For tumor samples showing aberrant SSCP bands, the relevant region of the gene was sequenced directly from a new PCR product alongside normal DNA. mice (P ϭ 0.016, Mann-Whitney U test), whereas heterozygous Myh deficiency had no effect (P ϭ 0.83, Mann-Whitney U test). Subanalysis of the three segments of small intestine showed that the increase in tumor number in Myh-deficient mice was more pronounced in the proximal and middle segments than in the distal segment (P Ͻ 0.01, ANOVA for interaction; Table 1 ). When adenomas were grouped according to size, it was evident that neither heterozygous nor homozygous Myh deficiency had a significant effect on the proportions of lesions that were Ͻ1 mm, 1 to 2 mm, and Ͼ2 mm in size, being ϳ60, 35, and 5%, respectively (P ϭ 0. Fig. 2) . However, the increase in cystic crypt number in Myh-deficient mice as compared with Myh wild-type mice was not statistically significant (P ϭ 0.17, Mann-Whitney U test). Histopathological analysis revealed that a subpopulation of cystic crypts displayed dysplastic changes (Fig. 2) . In general, animals with a high polyp count in the small intestine tended to have a high cystic crypt count (R 2 ϭ 0.57; P Ͻ 0.001, linear regression analysis).
RESULTS

Myh Deficiency Enhances Tumor Formation in the Small
No adenomas or cystic crypts were found in the small intestine of any of 15 (Table 1) . Thus, Myh-deficient mice showed an approximately 2-fold increase in ACF number compared with Myh wild-type mice (P ϭ 0.001, Mann-Whitney U test), whereas heterozygous Myh deficiency had no effect (P ϭ 0.10, Mann-Whitney U test). In all of the animals, ACFs occurred predominantly in the distal colon. Histopathological analysis of selected ACFs revealed mild dysplasia in all of the cases (Fig. 3) . Surprisingly, ACF numbers were not associated with colonic tumor numbers, which suggested that Min/ϩ /Myh ϩ/ϩ mice, the significant excess of tumors occurs because absent Myh activity leads to "second hits" that are distinct from allelic loss. The fraction of tumors that retained the Apc wild-type allele in Myh-deficient mice (ϳ19%) was, however, lower than the observed increase in tumor number (ϳ53%). This difference may be the result of chance but may also reflect a requirement for mutation in one or more additional genes for macroscopic polyp development. Alternatively, Myh deficiency may have some other effect in addition to increasing the intrinsic mutation rate.
Analysis of large-bowel polyps from each genotypic class revealed no significant difference in the frequency of allelic loss at Apc. We found that 6 (100%) of 6 
G:C3 T:A Truncating Somatic Mutations Occur in Adenomas from Myh-Deficient Apc
Min/ϩ Mice. All 29 small-bowel tumors without allelic loss at Apc from Apc Min/ϩ /Myh Ϫ/Ϫ mice were examined for somatic mutations in Apc. Mutations were detected in 3 (10%) polyps. All three changes were G:C to T:A transversions [2ϫ nucleotide (nt) 3919GϾT, nt4754CϾA] resulting in "stop" codons (2ϫ E1307X, S1585X). The sequence context around the E1307X mutations was AAAGAGA (Fig. 4), 
Adenomas from Myh-Deficient Apc
Min/ϩ Mice Do Not Harbor K-ras Mutations. Activating K-ras mutations occur in ϳ50% of sporadic colorectal adenomas in humans (32, 33) , and tumors from MYH-associated polyposis patients show an increased frequency of K-ras mutations as compared with tumors from familial adenomatous polyposis patients (18, 34) . In addition, about 75% of lung tumors from Myh and Ogg1 double-knockout mice harbor G to T mutations in K-ras codon 12 (19) creased adenomatous polyp number in the small bowel. In addition, Myh deficiency increased the frequency of mammary tumors. The magnitude of the increase in tumor number in the small intestine was correlated with the fraction of tumors that failed to show loss of the wild-type Apc allele. This association is consistent with studies on tumors from Apc Min/ϩ mice with deficiencies in the base excision repair protein Mbd4 or the MMR proteins Mlh1, Msh2, or Pms2 (24, (37) (38) (39) (40) (24, 37, 40) . A highly plausible explanation for the low frequency of somatic, truncating Apc mutations is that adenomas from Apc Min/ϩ mice are polyclonal, the contribution of each mutant allele to the tumor DNA too small to be detected in most cases (42) .
Detailed examination of both tumor size and histology failed to reveal any evidence of tumor progression in the small bowel of Apc Min/ϩ /Myh Ϫ/Ϫ mice by 120 to 130 days of age. These data are consistent with studies on tumors from Apc Min/ϩ mice with deficiencies in Mlh1, Msh2, or Pms2 (24, 38, 39) and suggest that Myh deficiency has a larger effect on tumor initiation than on progression in the small bowel. Apc Min/ϩ /Myh Ϫ/Ϫ mice showed a more pronounced increase in tumor number in the proximal and middle segments than in the distal segment of the small bowel. A similar pattern is observed in MYHassociated polyposis patients who sometimes develop duodenal polyps (4). MMR-deficient Apc Min/ϩ mice, by contrast, show a uniform increase in the number of small-bowel polyps (24) . The finding in Apc Min/ϩ /Myh Ϫ/Ϫ mice and MYH-associated polyposis patients may reflect variation in the level of oxidative stress throughout the small bowel, although it could also reflect variation in the level or activity of Myh protein or site-specific differences in functional redundancy.
Heterozygous Myh deficiency had no detectable effect on tumor development in Apc Min/ϩ mice or the frequency of allelic loss at Apc. Furthermore, inactivation of the wild-type Myh allele was very rare in these mice. Although these data must be interpreted with some caution because of the possible polyclonal origin of polyps in the mouse small intestine, they are consistent with our findings, in sporadic colorectal cancers from humans, that failed to detect somatic mutations or allelic loss at MYH (43) .
Besides intestinal adenomas, Apc Min/ϩ mice are predisposed to two types of lesions of unknown neoplastic potential, cystic crypts of the small intestine and ACFs of the colon. Cystic crypt multiplicity is increased in Apc Min/ϩ mice deficient in Mlh1 or treated with chemical carcinogens (23, 24) . Although our data were suggestive of a similar effect in Myh-deficient Apc Min/ϩ mice, the increase did not reach statistical significance. In contrast, Apc Min/ϩ /Myh Ϫ/Ϫ mice showed a significant, ϳ2-fold, increase in the number of ACFs, supporting a role of Myh deficiency in promoting the development of these lesions.
In conclusion, our data suggest that Myh deficiency leads to an increase in the intrinsic mutation rate. This increase is insufficient to cause intestinal tumorigenesis in our Myh-deficient mice on an otherwise wild-type genetic background but is made manifest when mice who already harbor the first step of tumorigenesis (Apc mutation) are studied. MYH deficiency may have a more profound effect on the mutation rate in humans, who are subjected to greater levels of oxidative stress in the intestine than are the laboratory mouse. Although we did not detect somatic K-ras mutations, we believe that the excess adenomas in Apc Min/ϩ /Myh Ϫ/Ϫ mice are a useful model of MYH-associated polyposis, allowing studies of molecular mechanisms or the evaluation of therapeutic agents. Furthermore, suppression of loss of the wild-type Apc allele, for example, by crossing Apc Min/ϩ /Myh Ϫ/Ϫ mice onto the AKR genetic background (44) , may produce a mouse model of MYH-associated polyposis in which most polyps develop as a result of defective base excision repair.
